Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today ...

By Amina Niasse (Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Per the chart above, roughly 35% of Hims & Hers float is sold short. Investors who short a stock are betting its price will fall. Short interest of 10% or more is considered unusually high. Not only ...

Hims & Hers Health has seen massive success, aided by the growing use of GLP-1 drugs. Click here to find out why I downgrade ...

Hims & Hers leverages ZAVA's expertise to enter Europe's weight-loss market, boosting growth and profitability. Read what ...

The E.U.'s universal healthcare policies make pharmaceuticals much more affordable relative to the U.S., meaning there could ...

As of early June, HIMS stock is hovering around $55 per share, representing a roughly 33% decline from its all-time high reached in early 2025. Indeed, Hims & Hers has subjected investors to a ...

Hims & Hers Health will acquire Zava, expanding the company’s services to Ireland, France and Germany and growing its active ...

Hims & Hers expanding in Europe with the purchase of London-based digital health platform ZAVA. The acquisition gives the ...

(Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to changing ...